研究摘要：肾切除术后辅助使用尼伐普利酮加伊匹单抗与安慰剂对于局部肾细胞癌（CheckMate 914）：一项双盲、随机、3期临床试验。
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
发表日期：2023 Sep 02
作者：
Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C Goh, Dingwei Ye, Alejo Lingua, Jean-Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
来源：
Cell Death & Disease
摘要：
本文摘要报告了《CheckMate 914》研究（NCT03138512；EudraCT 2016-004502-34）的A部分。在去除肾细胞癌（RCC）的手术后，患有癌症复发高风险的人们接受了尼伐单抗与伊匹单抗（辅助治疗）或安慰剂治疗，以观察是否减小了癌症复发的风险。研究结果显示，与安慰剂治疗相比，辅助治疗的尼伐单抗与伊匹单抗并未改变RCC复发或死亡的风险。此外，接受尼伐单抗与伊匹单抗治疗的患者与接受安慰剂治疗的患者相比，副作用更多（89%对57%）。© 2023. 作者。
This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).© 2023. The Author(s).